Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging drugs for chronic hepatitis C.

Girish Mahadeorao Bhopale1, Rabindra Kumar Nanda

  • 1Research and Development Division, Hindustan Antibiotics Limited, Pimpri, Pune 411018, India.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|July 19, 2005
PubMed
Summary

Current Hepatitis C virus (HCV) treatments have limitations, driving the development of new therapies. Emerging drugs, including novel interferons and RNA-based agents, show promise for treating chronic HCV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Societyยท2013
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) is a significant global health concern, leading to chronic hepatitis, liver cirrhosis, and liver cancer.
  • Current standard therapy for chronic HCV involves pegylated interferon and ribavirin, but it has limitations in efficacy and tolerability.

Purpose of the Study:

  • To review the current therapeutic landscape for Hepatitis C virus (HCV) infection.
  • To highlight promising emerging drug categories and their developmental status for HCV treatment.

Main Methods:

  • Literature review of existing and investigational therapies for Hepatitis C.
  • Analysis of drug categories including novel interferons, ribavirin analogs, and RNA-based therapeutics.

Main Results:

Related Experiment Videos

  • Existing combination therapy (pegylated interferon and ribavirin) faces challenges with efficacy and side effects.
  • Several novel therapeutic classes are in clinical development, offering potential improvements.

Conclusions:

  • The limitations of current HCV therapy necessitate the exploration of new drug classes.
  • Emerging agents like antisense oligonucleotides, siRNAs, and enzyme inhibitors represent the future of Hepatitis C treatment.